您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Regorafenib hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Regorafenib hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Regorafenib hydrochloride图片
CAS NO:835621-07-3
包装与价格:
包装价格(元)
5 mg电议
1 mL*10 mM(in DMSO)电议

产品名称
BAY73-4506 hydrochloride
瑞戈非尼盐酸盐
产品介绍
RegoRafenib Hydrochloride 是一种新型口服多激酶抑制剂,可抑制血管生成、基质和致癌受体酪氨酸激酶,具有强大的临床前抗肿瘤活性。它靶向作用于VEGFR1/2/3、PDGFRβ、Kit、RET和Raf-1,IC50值分别为 13/4.2/46、22、7、1.5 和 2.5 nM。

产品描述

Regorafenib Hydrochloride is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

体外活性

Regorafenib inhibits additional angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF.

体内活性

Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts.?In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 hr after the last dosing and correlated with tumor growth inhibition (TGI).?A significant reduction in tumor microvessel area was observed in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg.?Regorafenib exhibited potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages observed in breast MDA-MB-231 and renal 786-O carcinoma models.?Pharmacodynamic analyses of the breast model revealed strong reduction in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2[1].

Cas No.

835621-07-3

分子式

C21H16Cl2F4N4O3

分子量

519.28

别名

BAY73-4506 hydrochloride;瑞戈非尼盐酸盐

储存和溶解度

DMSO:5.6 mg/mL (10.78 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years